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Abstract
© 2016 Wiley Periodicals, Inc. Over the past decade, microRNA-142 (miR-142) is emerging as a
major  regulator  of  cell  fate  decision  in  the  hematopoietic  system.  However,  miR-142  is
expressed in  many other  tissues,  and recent  evidence suggests  that  it  may play a  more
pleiotropic role during embryonic development. In addition, miR-142 has been shown to play
important functions in disease. miR-142 displays a functional role in cancer, virus infection,
inflammation, and immune tolerance. Both a guide strand (miR-142-3p) and passenger strand
(miR-142-5p) are generated from the miR-142 hairpin. miR-142-3p and -5p display overlapping
but also independent target genes. Loss of function mouse models (genetrap, global knock out
[KO], and conditional KO) have been reported and support the important role of miR-142 in
different  biological  processes.  This  review  will  summarize  the  abundant  literature  already
available for miR-142 and will lay the foundation for future works on this important microRNA.
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